Dr Reddy’s Laboratories on Friday reported a 33.02 per cent soar in its consolidated revenue after tax (PAT) at Rs 1,482.2 crore within the September 2023 quarter, led by the US generics market. Its consolidated complete income from operations throughout July-September 2023 rose 9 per cent to Rs 6,902.6 crore, in contrast to Rs 6,331.8 crore within the 12 months-in the past interval.
The firm had posted a consolidated revenue after tax of Rs 1,114.2 crore in the identical quarter a 12 months in the past, Dr Reddy’s Laboratories Ltd (DRL) stated in a regulatory submitting.
DRL’s complete bills within the September quarter had been up 11.14 per cent to Rs 5,305.1 crore. Total earnings of DRL within the September quarter was at Rs 7,217.6 crore, up 13.25 per cent.
G V Prasad, co-chairman & MD of Dr Reddy’s, stated, “We delivered another quarter of strong results with highest ever sales and profits, driven by market share gains & momentum in our US generics business and robust growth in Europe. We are continuing to strengthen our pipeline both organically and through business development to drive growth and create differentiation.”
DRL’s international generics posted a income of Rs 6,113 crore in Q2, up 9.14 per cent from the 12 months-in the past quarter, pushed by North America, rising markets and Europe. North America’s income was at Rs 3,170 crore, a development of 13 per cent, whereas that of Europe was at Rs 528.6 crore, with a development of 26 per cent, the corporate stated.
While its income from ‘Pharmaceutical Services and Active Ingredients’ was at Rs 962.5 crore, up 16.95 per cent, as towards Rs 823 crore, a 12 months earlier than. Shares of Dr Reddy’s Laboratories Ltd on Friday settled at Rs 5,385.55 on BSE, down 0.72 per cent from the earlier shut.
